REPORTS. Externally Funded Research Programs CANCER COUNCIL QLD. New research grants. Cancer Council charitable funding amount 2016
|
|
- Alexander Wells
- 6 years ago
- Views:
Transcription
1 CANCER COUNCIL QLD Externally Funded Programs New research grants Other grant Prof Mark Smyth - QIMR Checkpoint blockade and denosumab in the treatment of established primary and metastatic s. Skin & Dr Eloise Dray - Deciphering the role of the protein phosphatase EYA4 in genomic maintenance and breast avoidance. A/Prof Raymond Steptoe - Diamantina Does lymphoma avoid immune destruction by inducing T-cell tolerance? Lymphoma Dr Dominic Ng - The University of Mitotic spindle regulation by a novel Aurora A control mechanism. Prevention Dr Stacey Edwards - QIMR Identifying new breast genes from GWAS. Dr Bryan Day - QIMR Advancing a novel therapy to target brain stem cells. Brain A/Prof Vicki Whitehall - QIMR Sessile serrated adenoma prevention in a preclinical study. Bowl prevention Dr Michael Piper - The Regulation of stem cell differentiation during cerebella development and medulloblastoma. Childhood Brain Prof Rajiv Khanna - QIMR Impact of immune contexture on clinical outcome of adoptive immunotherapy Prevention 93
2 grant Other Prof Lisa Chopin - The ghrelin receptor antisense long non-coding RNA, GHSROS, as a potential target for prostate therapy. Dr Mathias Francois - The SOX18-VEGF cross-regulation during angiogenesis and blood vascular development. Basic Science Prof George Muscat - The Elucidating the role of the nuclear hormone receptor RORy1 in breast. Prof Judith Clements - Targeting kallikrein proteases to improve treatment options for ovarian. Ovarian Dr Kate Gartlan - QIMR RORyt inhibition as a novel therapeutic for the prevention of graft-versus-host disease after allogeneic stem cell transplantation. Leukemia Dr Fares Al-Ejeh - QIMR The MEK5-ERK5 pathway in triple negative breast : progression and therapy. Travelling fellowships Provision for special projects By invitation $65,000 $0 $65,000 All s By invitation $56,306 $0 $56,306 All s RESEARCH FUNDED (new ) $1,621,306 $0 $1,621,306 Continuing research grants Prof Geoffrey Hill - QIMR Understanding and optimizing Graft-versus-Myeloma effects after bone marrow transplantation. Blood Prof Kum Kum Khanna - QIMR The role of PC4 in the tumorigenesis and metastasis of breast. 94 Forum Volume 40 Number 2 July
3 grant Other A/Prof Amanda Spurdle -QIMR Clinical classification of BRCA1/2 gene variants. Prof Andreas Suhrbier - QIMR Regulation of mtorc2 and Ras signalling by Sin1 isoforms in pancreatic. Pancreatic Prof Mark Smyth - QIMR A new checkpoint of immunotherapy. Immunotherapy Dr Michele Teng - QIMR The role of IL-23 associated cytokines in immunology. Skin Dr Roberta Mazzieri - The Targeting the proangiogenic and immunosuppressive tumour microenvironment in primary and metastatic breast. Dr Murugan Kalimutho - The Cep55 is a determinant of aneuploidy cell fate in breast. Dr Lachlan Coin - The University of Using somatic copy number and methylation profiling of circulating tumour DNA to monitor heterogeneous tumour development in breast. Prof Thomas Gonda - The A small molecule screen for inhibitors of the MYB oncoprotein. Leukemia A/Prof Richard Sturm - The Human pigmentation pathway in UV-protection and mechanisms of melanoma risk. Skin Prof Brandon Wainwright - The University of A synthetic lethal based approach for the treatment of medulloblastoma. Childhood Brain 95
4 grant Other A/Prof Helen Blanchard - Griffith University Development of inhibitors targeting the promoting protein galectin - 3. All s Prof Judith Clements - PSA coding variants: functional analysis, multiethnic association and risk models for prostate. Dr Elke Hacker - New technologies in skin prevention. Skin A/Prof John Hooper - Mater, Targeting CDCP1 to reduce tumour burden and ascites in clear cell ovarian. Ovarian Prof Peter Koopman, Nodal/Cripto signalling in germ cell development and tumorigenesis. Testicular Prof Nigel McMillan, Griffith University Novel therapeutic targets for HPV-driven s. $97,000 $0 $97,000 HPV s Prof Colleen Nelson, Development of YB-1 as a therapeutic target in advanced prostate. Prof Kenneth O Byrne, MyRIP and exosomes function to control genomic stability. Basic science Dr Allison Pettit, Mater, Macrophages facilitate prostate bone metastasis. Dr Pamela Pollock, Understanding FGFR2 activation in endometrial : Novel mutations, differences in spatio-temporal signaling and alternative activating spliceforms. Endometrial 96 Forum Volume 40 Number 2 July
5 grant Other Prof Alpha Yap, Controlling the Rho off-switch: a novel target in breast. PhD Scholarship Miss Arabella Youing, QIMR Targeted therapy and immunotherapy in breast. $30,000 $0 $30,000 PhD Scholarship Dr Matthew Roberts, Improving the early detection of prostate : a noninvasive, systems biology approach. $30,000 $0 $30,000 Senior Fellowship Prof Nicholas Saunders - Translating basic science into better treatments. $159,845 $0 $159,845 Basic science Senior Fellowship A/Prof Sandi Hayes - Exercise is medicine: a nonpharmacological approach to care. $138,627 $0 $138,627 All s Chair of Prevention Prof Michael Kimlin - the Sunshine Coast CCQ/Univ. Sunshine Coast Joint Professor of Prevention. Prevention CCQ/QCOG Clinical Trial Data Manager Grants Gold Coast University Hospital Icon Care - HOCA Centre Mater Health Services - Oncology & Palliative Care Nambour Hospital Oncology Australia Genesis Care Princess Alexandra Hospital - (Surgery,Haematology & Oncology, Radiation Oncology) Radiation Oncology Services - Mater Centre $459,051 $764,063 $1,223,114 All s Royal Brisbane and Women s Hospital - Gynaecological, Oncology, Radiation Oncology, Brisbane Colorectal Group Lady Cilento Children s Hospital Townsville Hospital Wesley RESEARCH FUNDED (continuing ) $3,214,523 $764,063 $3,978,586 EXTERNAL FUNDED RESEARCH PROGRAMS (including new and continuing research grants) $4,835,829 $764,063 $5,599,892 97
6 grant Other Internally Funded Programs Continuing research grants Viertel Centre $4,319,683 $1,150,925 $5,470,608 Epidemiology - in Indigenous Australians - in Children - Outcomes - UV Exposure, Vitamin D and Melanoma - Analysis and reporting of statistics and patterns $134,989 $144,172 $279,161 Psycho-oncology - Developing accessible and effective supportive care interventions - Identifying needs for patients and carers $89,350 $305,754 $395,104 Community Engagement - Building capacity for control agencies - Meeting the needs of regional and rural communities $373,125 $37,106 $410,231 Australian Paediatric Registry $57,032 $63,924 $120,956 Registry $396,779 $939,000 $1,335,779 INTERNALLY FUNDED RESEARCH PROGRAMS (continuing research grants) $5,370,958 $2,640,881 $8,011,839 RESEARCH FUNDED CANCER COUNCIL QLD $10,206,787 $3,404,944 $13,611, Forum Volume 40 Number 2 July
Characterisation of the function and therapeutic potential of EphA2 and EphA3 in prostate cancer
CANCER COUNCIL QLD EXTERNALLY FUNDED RESEARCH PROGRAMS New Research Grants amount amount for Prof Andrew Boyd Research Dr Glenn Boyle Research Prof Judith Clements Dr Nicole Cloonan Research Dr Bryan Day
More informationMarch 2018 (i2i-18) Competition Awarded Innovation to Impact Grants Listed by panel in alphabetical order
I1a March 2018 (i2i-18) Competition Awarded Innovation to Impact Grants Listed by panel in alphabetical order Biomarkers and Genomics Brooks-Wilson, Angela Genetic buffering in cancer The risk of many
More informationDr Graeme Suthers: The genetic basis of cancer
Dr Graeme Suthers: The genetic basis of cancer Dr Suthers is the head of the Familial Cancer Unit at the Women s and Children s hospital. He will begin the evening with an introduction to cancer and its
More informationSaving lives. Beating cancer.
Saving lives. Beating cancer. Annual Report 2014 About Us OUR VISION is for a cancer free future. Our mission Medical research has successfully beaten most disease it will beat cancer. Cancer Council Queensland
More informationAccredited Sites for Advanced Training HAEMATOLOGY June 2018
Accredited Sites for Advanced Training HAEMATOLOGY June 2018 Core Training in Haematology can only be undertaken in an accredited training setting. Applicants are advised that the position applied for
More informationBIOLOGY OF CANCER. Definition: Cancer. Why is it Important to Understand the Biology of Cancer? Regulation of the Cell Cycle 2/13/2015
BIOLOGY OF CANCER Why is it Important to Understand the Biology of Cancer? Cynthia Smith, RN, BA, MSN, AOCN Oncology Clinical Nurse Specialist Harrison Medical Center Definition: Cancer Regulation of the
More informationSummary of Strategic Competitive Analysis and Publication Planning
Summary of Strategic Competitive Analysis and Publication Planning Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Briefing
More informationAmerican Cancer Society, Inc. Extramural Grants
Page: 1 Cancer Control Career Development Award for Primary Care Physicians (CCCDA) CCCDA-14-013-01 Cole, Allison M., MD MENTOR: Baldwin, Laura-Mae, MD, MPH Department of Family Medicine Improving Colorectal
More informationLecture 1: Carcinogenesis
Lecture 1: Carcinogenesis Anti-cancer (oncology agents): These are perhaps the most dangerous of drugs, other than the narcotic analgesics. This is due to their toxicities. Killing or inhibiting cancer
More informationWhat are brain and spinal cord tumours? Contents
13 11 20 Information and support What are brain and spinal cord tumours? Contents The brain and spinal cord Brain function What is a brain or spinal cord tumour? What types of tumours are there? How common
More informationBDHP Chronic Disease Theme Forum
BDHP Chronic Disease Theme Forum Friday 15 June 2018 Translational Research Institute (TRI), Woolloongabba, Brisbane, Queensland REGISTER TO ATTEND THIS FREE EVENT Metro South Hospital and Health Service
More informationCancer immunity and immunotherapy. General principles
1 Cancer immunity and immunotherapy Abul K. Abbas UCSF General principles 2 The immune system recognizes and reacts against cancers The immune response against tumors is often dominated by regulation or
More informationLudwig Presence at 2014 AACR Annual Meeting
Saturday, April 5, 2014 Michael T. Hemann, PhD, Ludwig MIT April 5 at 10:15 AM - 10:40 Educational Room 7, San Intratumoral Heterogeneity and Its Effects on Drug Response and Disease Relapse Targeting
More informationSummary of Research and Writing Activities in Oncology
Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationSCOTTISH ONCOLOGY SUMMIT Double Tree by Hilton, Dunblane Hydro, Dunblane 1 st - 2 nd September 2017
Friday 1 st September 1300h 1400h Lunch (arrival, registration at conference foyer, coffee and sponsors exhibition) 1400h 1420h Prof Robert Jones Welcome/Announcements 1430h 1600h Parallel sessions: Lung
More informationCUP: Treatment by molecular profiling
CUP: Treatment by molecular profiling George Pentheroudakis Professor of Oncology Medical School, University of Ioannina Greece Chair, ESMO Guidelines September 2018 Enterprise Interest No disclosures.
More informationArmstrong, Bruce (Prof.)
Presenter: Armstrong, Bruce (Prof.) Title of Lecture: Cancer Control Research COMMONWEALTH OF AUSTRALIA Copyright Regulations 1969 WARNING This material has been reproduced and communicated to you by or
More informationCancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous
Session8 Medical Genetics Cancer Genetics J avad Jamshidi F a s a U n i v e r s i t y o f M e d i c a l S c i e n c e s, N o v e m b e r 2 0 1 7 What is Cancer? Uncontrolled growth of cells Not all tumors
More informationInformation. about cancer
1 Information about cancer This chapter may help you answer simple questions about what cancer is and how it is treated. There are more than 200 different types of cancer and a range of treatments. Being
More informationCOURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16
COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 Tumor Immunology M. Nagarkatti Teaching Objectives: Introduction to Cancer Immunology Know the antigens expressed by cancer cells Understand
More information2 Diagnosis and Staging of Cancer 2.1 Pathophysiology of cancer 2.2 Classification and staging 2.3 Diagnostic measures for specific cancer types
Oncology Nursing Sub-Specialty Module Reference: Gobel B. M., Triest-Robertson S. & Vogel W.H. (Eds). (205). Advanced Oncology Nursing Certificate Review and Resources Manual. Pittsburgh: Oncology Nursing
More informationFACULTY MEMBERSHIP APPLICATION Tulane Cancer Center
FACULTY MEMBERSHIP APPLICATION Tulane Cancer Center 1430 Tulane Ave., Box SL-68, New Orleans, LA 70112-2699 J. Bennett Johnston Building, Mezzanine (Floor 1A), Suite A102 (504) 988-6060, fax (504) 988-6077,
More informationPRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019
MONDAY, JUNE 3, 2019 7:30 AM - 9:15 AM HIGHLIGHTS OF THE DAY 8:00 AM - 9:00 AM S 8:00 AM - 9:15 AM S S 8:00 AM - 11:00 AM S Highlights of the Day Session II Bringing New and Innovative Glioblastoma Treatments
More informationOncology 101. Cancer Basics
Oncology 101 Cancer Basics What Will You Learn? What is Cancer and How Does It Develop? Cancer Diagnosis and Staging Cancer Treatment What is Cancer? Cancer is a group of more than 100 different diseases
More informationBeat Cancer Project funding 2018
Beat Cancer Project funding 2018 The following document provides an overview of the research projects that have been awarded Beat Cancer Project funding for 2018. Funding is sorted by administering institution
More informationReprogramming Tumor Associated Dendritic Cells for Immunotherapy
Reprogramming Tumor Associated Dendritic Cells for Immunotherapy Edgar Engleman, M.D. Professor of Pathology and Medicine Stanford University Disclosures: Founder of Dendreon, a biotechnology company that
More informationFuture Perspectives in mpca. Michel Ducreux, MD, PhD Gustave Roussy Villejuif, France
Future Perspectives in mpca Michel Ducreux, MD, PhD Gustave Roussy Villejuif, France Number of Novel Therapies and Targets in Pancreatic Cancer Are Expanding Garrido-Laguna I, et al. Nat Rev Clin Oncol.
More informationLurie Cancer Center (LCC) OncoSET: Bringing Real-Time Precision Medicine to Patients
Lurie Cancer Center (LCC) OncoSET: Bringing Real-Time Precision Medicine to Patients Massimo Cristofanilli, MD Professor of Medicine Associate Director of Translational Research and Precision Medicine
More informationPersonalized medicine - cancer immunotherapy
Personalized medicine - cancer immunotherapy Özcan Met, PhD Senior Staff Scientist, Cell Therapy Director Center for Cancer Immune Therapy Department of Hematology Department of Oncology University Hospital
More informationTrends and disparities in cancer in Aotearoa/ NZ
Trends and disparities in cancer in Aotearoa/ NZ Professor Diana Sarfati #cancercrossroads @DiSarfati Why cancer? Estimated number of incident cases from 2018 to 2040 in New Zealand, all cancers, both
More informationOverview of Cancer. Mylene Freires Advanced Nurse Practitioner, Haematology
Overview of Cancer Mylene Freires Advanced Nurse Practitioner, Haematology Aim of the Presentation Review basic concepts of cancer Gain some understanding of the socio-economic impact of cancer Order of
More informationAllinaHealthSystems 1
Overview Biology and Introduction to the Genetics of Cancer Denise Jones, MS, CGC Certified Genetic Counselor Virginia Piper Cancer Service Line I. Our understanding of cancer the historical perspective
More informationTUMOR M ARKERS MARKERS
TUMOR MARKERS M.Shekarabi IUMS Definition Many cancers are associated with the abnormal production of some molecules l which h can be measured in plasma. These molecules are known as tumor markers. A good
More informationFighting Cancer with Data: Perspectives on MD Anderson Moon Shot Program
Fighting Cancer with Data: Perspectives on MD Anderson Moon Shot Program Joxel Garcia, MD, MBA Executive Director, Cancer Prevention and Control Platform Member, Moon Shots Program Leadership Team The
More informationFocus on Immunotherapy as a Targeted Therapy. Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct
Focus on Immunotherapy as a Targeted Therapy Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct 18 2018 Disclosures I have nothing to disclose that is relevant to this presentation. Immunology @ Deeley
More informationAmerican Cancer Society, Inc. Extramural Grants
Page: 1 Graduate Scholarships in Cancer Nursing Practice (GSCNP) GSCNP-17-124-01 Ranney, Lori, MSN MENTOR: Foote, Jane, EdD, MSN, RN Winona State University MN Graduate Scholarship in Cancer Nursing Practice
More informationImmunotherapy: The Newest Treatment Route
Immunotherapy: The Newest Treatment Route IWMF Patient Forum, Phoenix, AZ Madhav Dhodapkar, MD Professor of Medicine and Immunobiology Chief, Section of Hematology Yale University or the Oldest William
More informationBIT 120. Copy of Cancer/HIV Lecture
BIT 120 Copy of Cancer/HIV Lecture Cancer DEFINITION Any abnormal growth of cells that has malignant potential i.e.. Leukemia Uncontrolled mitosis in WBC Genetic disease caused by an accumulation of mutations
More informationPersonalised Medicine in Practice. Dr Ingrid Slade MBChB, PhD, MRCPCH, MFPH Dr Chris Spencer DPhil Dr Gabriele De Luca MD, DPhil
Personalised Medicine in Practice Dr Ingrid Slade MBChB, PhD, MRCPCH, MFPH Dr Chris Spencer DPhil Dr Gabriele De Luca MD, DPhil Personalised Medicine in Cancer Care Personalised Medicine in Cancer Care
More informationOVARIAN CANCER SYMPOSIUM
OVARIAN CANCER SYMPOSIUM Immunotherapy and targeted therapy in ovarian cancer supported by in alliance with 5 MAY 2018 MELBOURNE EVENT PROGRAM 9:30am 10:00am Registration Welcome: Jane Hill (OCA CEO) SESSION
More informationMidland Region All Boards Development Days. Midland Cancer Network. 15, 16 October, 2015
Midland Region All Boards Development Days Midland Cancer Network 15, 16 October, 2015 NZ cancer incidence 1948-2011 Source: NZ Cancer 0.0 50.0 100.0 150.0 200.0 250.0 300.0 350.0 400.0 0 5000 10000 15000
More informationREGISTER TO ATTEND THIS FREE EVENT. brisbane diamantina health partners
BDHP Brain and Mental Health Conference Translational research in Neuroscience: Bridging the gap between basic science and clinical practice Tuesday 28 August 2018 Bancroft Auditorium QIMR Berghofer Medical
More informationThe feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients
The feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients ASSC Scientific Meeting 13 th October 2016 Prof Andrew Barbour UQ SOM
More informationCANCER Uncontrolled Cell Division
CANCER Uncontrolled Cell Division What is cancer? Why does it occur? Where does it occur? Benign vs. Malignant? Types of Cancer (3 main groups) There are over 200 different types of cancer 1) Carcinomas
More information- A cancer is an uncontrolled, independent proliferation of robust, healthy cells.
1 Cancer A. What is it? - A cancer is an uncontrolled, independent proliferation of robust, healthy cells. * In some the rate is fast; in others, slow; but in all cancers the cells never stop dividing.
More information2008 Oncology Pharmacy Preparatory Review Course Learning Objectives
2008 Oncology Pharmacy Preparatory Review Course Learning Objectives Session 1 Symptom Management, Part I, II & III Teresa A. Mays, Pharm D., BCOP Director, Investigational Drug Department San Antonio,
More informationSupplementary Tables. Supplementary Figures
Supplementary Files for Zehir, Benayed et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients Supplementary Tables Supplementary Table 1: Sample
More informationCancer as a Complex Adaptive System: Cancer Progression, Evolutionary Dynamics and Implications for Treatment
BIO 302: September 26, 2018 Cancer as a Complex Adaptive System: Cancer Progression, Evolutionary Dynamics and Implications for Treatment Dr. George Poste Chief Scientist, Complex Adaptive Systems Initiative
More informationBiochemistry of Cancer and Tumor Markers
Biochemistry of Cancer and Tumor Markers The term cancer applies to a group of diseases in which cells grow abnormally and form a malignant tumor. It is a long term multistage genetic process. The first
More informationLecture 1: Carcinogenesis
Lecture 1: Carcinogenesis Anti-cancer (oncology agents): These are perhaps the most dangerous of drugs, other than the narcotic analgesics. This is due to their toxicities. Killing or inhibiting cancer
More informationCurable cancers: Progress in Oncology. Prof.Dilip Kumar Dhar Princicipal & Professor of Medicine MH Samorita Hospital & Medical College, Dhaka.
Curable cancers: Progress in Oncology Prof.Dilip Kumar Dhar Princicipal & Professor of Medicine MH Samorita Hospital & Medical College, Dhaka. Introduction Cancer is one of the leading causes of morbidity
More information1 Cancer Council Queensland, Brisbane, Queensland, Australia.
Title: Diagnosis of an additional in situ does not influence survival for patients with a single invasive : A registry-based follow-up study Authors: Danny R Youlden1, Kiarash Khosrotehrani2, Adele C Green3,4,
More informationBY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Cancer is a group of more than 100 different diseases that are characterized by uncontrolled cellular growth,
More information3 rd Berlin Cancer Retreat - Agenda
3 rd Berlin Cancer Retreat - Agenda Wednesday, 5 October 2016 8:30 9:00 Registration 9:00 9:10 Welcome and Introduction Program Exploitation of Oncogenic Mechanisms Ulrike Stein 9:10 9:25 Targeting Myc
More informationSaturday 25th August Queensland Acoustic Neuroma Conference. The 7th Biennial David Brown-Rothwell Memorial
Princess Alexandra Hospital Qld Skull Base Unit PAH in association with Qld Acoustic Neuroma Association & Audiology Australia The 7th Biennial Queensland Acoustic Neuroma Conference Convenors: The Queensland
More informationRECENT RESEARCH BREAKTHROUGHS
RECENT RESEARCH BREAKTHROUGHS Who we are QIMR Berghofer is a world-leading medical research institute, renowned for our efforts in both discovery and translational (real patient setting) research. We research
More informationBiology Based Cancer Interception
Biology Based Cancer Interception Waun Ki Hong, M.D. American Cancer Society Professor Former Head Division of Cancer Medicine UT MD Anderson Cancer Center Disclosures SAB : Janssen,Medimmune,Molecular
More informationCaring for cancer patients with comorbidity
Caring for cancer patients with comorbidity Comorbidity among Indigenous Australian cancer patients Chair: Diana Sarfati Speaker: Patricia Valery Session code: CTS.2.143-2 www.worldcancercongress.org Aboriginal
More informationCANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients
CANCER MEDICINES IN DEVELOPMENT 2018 REPORT JUST THE FACTS MORE THAN 1.7 M ESTIMATED NEW CASES OF CANCER IN 2018 IN THE UNITED STATES MORE THAN 609,000 U.S. CANCER DEATHS ARE EXPECTED IN 2018 SINCE PEAKING
More informationImmunology CANCER IMMUNOLOGY
Immunology د. عائدة الدرزي Lec. 6 CANCER IMMUNOLOGY Oncogenesis (passes through two stages): 1- Reversible change Normal transformed cells 2- Irreversible change Transformed oncogenic cells Factors causing
More informationConditions. Name : dummy Age/sex : xx Y /x. Lab No : xxxxxxxxx. Rep Centre : xxxxxxxxxxx Ref by : Dr. xxxxxxxxxx
Name : dummy Age/sex : xx Y /x Lab No : xxxxxxxxx Rep Centre : xxxxxxxxxxx Ref by : Dr. xxxxxxxxxx Rec. Date : xx/xx/xx Rep Date : xx/xx/xx GENETIC MAPPING FOR ONCOLOGY Conditions Melanoma Prostate Cancer
More informationTHE ALAN COOPER EPIDERM LECTURE
THE ALAN COOPER EPIDERM LECTURE THE FUTURE OF EARLY MELANOMA DETECTION presented by MD, FACD, FAHMS Chair in Dermatology Director, Dermatology Research Centre, The University of Queensland 6:00pm, Friday
More informationCancer statistics (US)
Disclosure I have no financial relationships to disclose Biology and Introduction to the Genetics of Cancer Vickie Matthias Hagen, MS, CGC Certified Genetic Counselor Virginia Piper Cancer Service Line
More informationTHE MODERN GYNECOLOGIC EXAMINATION & SCREENING FOR GYNECOLOGIC MALIGNANCIES
THE MODERN GYNECOLOGIC EXAMINATION & SCREENING FOR GYNECOLOGIC MALIGNANCIES Denise Uyar, MD Associate Professor OB/GYN Chief Gynecologic Oncology Medical College of Wisconsin April 12, 2019 NO DISCLOSURES
More informationCancer. October is National Breast Cancer Awareness Month
Cancer October is National Breast Cancer Awareness Month Objectives 1: Gene regulation Explain how cells in all the different parts of your body develop such different characteristics and functions. Contrast
More informationStructured Pathology Reporting of Cancer Newsletter
Structured Pathology Reporting of Cancer Newsletter Welcome to the second quarterly edition of the Structured Pathology Reporting of Cancer newsletter. This newsletter is intended to provide information
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationTumour Markers. For these reasons, only a handful of tumour markers are commonly used by most doctors.
Tumour Markers What are Tumour Markers? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer
More informationEmerging Targets in Immunotherapy
Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy
More informationSupporting Cancer Council Queensland
Supporting Cancer Council Queensland About Cancer Council Queensland CANCER RESEARCH IN ACTION Our mission Reducing the burden of cancer. Cancer Council Queensland (CCQ) raises funds that are dedicated
More informationThe table below presents the summary of observed geographic variation for incidence and survival by type of cancer and gender.
Results and Maps Overview When disparities in cancer incidence and survival are evident, there are a number of potential explanations, including but not restricted to differences in environmental risk
More informationEmerging Tissue and Serum Markers
Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice
More informationTumor Markers & Cytopathology
Tumor Markers & Cytopathology Objectives: After learning, student should be able to 1. Describe the basic concepts of tumor markers and Asst. Prof. Prasit Suwannalert, Ph.D. (Email: prasit.suw@mahidol.ac.th)
More informationTargeting tumour associated macrophages in anti-cancer therapies. Annamaria Gal Seminar Series on Drug Discovery Budapest 5 January 2018
Targeting tumour associated macrophages in anti-cancer therapies Annamaria Gal Seminar Series on Drug Discovery Budapest 5 January 2018 Macrophages: Professional phagocytes of the myeloid lineage APC,
More informationChapter 20 Lecture Outline
Chapter 20 Lecture Outline See separate PowerPoint slides for all figures and tables preinserted into PowerPoint without notes. Copyright 2016 McGraw-Hill Education. Permission required for reproduction
More informationCancer Epidemiology Centre $3,303,000 $3,311,000 $6,614,000. Centre for Behavioural Research in Cancer $1,409,000 $3,231,000 $4,640,000
REPORTS INTERNALLY FUNDED RESEARCH PROGRAMS Program Cancer Epidemiology Centre $3,303,000 $3,311,000 $6,614,000 Centre for Behavioural in Cancer $1,409,000 $3,231,000 $4,640,000 Nigel Gray Fellowship Group
More informationTHE CENTRE OF RESEARCH EXCELLENCE FOR THE STUDY OF NAEVI
THE CENTRE OF RESEARCH EXCELLENCE FOR THE STUDY OF NAEVI @NaeviCRE OUR RESEARCH PARTNERS Naevi and Melanoma Number of naevi is the strongest risk predictor for melanoma Many melanomas arise adjacent to
More informationClinical: Ipilimumab (MDX-010) Update and Next Steps
Clinical: Ipilimumab (MDX-010) Update and Next Steps Geoffrey M. Nichol, M.D., M.B.A. Senior Vice President, Product Development Medarex, Inc. R&D Day December 9, 2005 Ipilimumab: New Class of Cancer Therapy
More informationAmerican Cancer Society, Inc. Extramural Grants
Page: 1 Doctoral Degree Scholarship in Cancer Nursing (DSCN) DSCN-17-079-01 Beckmann, Nicole, MSN MENTOR: Foster-Akard, Terrah L., PhD, RN, CPNP Vanderbilt University School of Nursing Parent Posttraumatic
More informationPractice of Medicine-1 Ovarian Cancer Clinical Correlation
Practice of Medicine-1 Ovarian Cancer Clinical Correlation Amir A. Jazaeri, M.D. Assistant Professor, Division of Gynecologic Oncology American Cancer Society Female Cancers 2000 Statistics Reprinted by
More informationNAACR Treatment Webinar Quiz 1
NAACR Treatment Webinar Quiz 1 1. Which of the following would NOT be considered cancer-directed treatment? a. Hemicolectomy b. Incisional biopsy c. Whole breast radiation d. MRI e. All of the above f.
More informationCancer Genomics 101. BCCCP 2015 Annual Meeting
Cancer Genomics 101 BCCCP 2015 Annual Meeting Objectives Identify red flags in a person s personal and family medical history that indicate a potential inherited susceptibility to cancer Develop a systematic
More informationAction to Cure Kidney Cancer Campaign to Fund Kidney Cancer Research
Action to Cure Kidney Cancer 2016 Campaign to Fund Kidney Cancer Research Kidney Cancer Facts 9 th most common cancer in the U.S. Until recently, 3 rd highest rate of increasing incidence of all cancers
More information2016 CRUK Lung Cancer Centre of Excellence Student/Postdoc Winter Workshop Programme
2016 CRUK Lung Cancer Centre of Excellence Student/Postdoc Winter Workshop Programme Thursday 1 st December 2016 09.15am 10.00am Registration and Refreshments 10.15am 10.30am Welcome 10.30am 11.15am Opening
More informationPROGRAMME. Chair: Dr. Darran O Connor, Senior Lecturer (Clinical Pharmacology) at the Royal College of Surgeons in Ireland
PROGRAMME 10:30 11:00 Registration and coffee 11:00 11:10 Welcome address: Prof. William Gallagher, Director of the UCD Conway Institute, Professor of Cancer Biology at UCD and Director of BREAST-PREDICT
More informationIs Prostate Cancer Amenable to Immunotherapy Approaches? New Frontiers in Urologic Oncology, September 12, 2015
Is Prostate Cancer Amenable to Immunotherapy Approaches? New Frontiers in Urologic Oncology, September 12, 2015 J. J. Mulé Associate Center Director, Translational Research U.S. Senator Connie Mack & Family
More informationTHE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum
More informationCANCER IN TASMANIA INCIDENCE AND MORTALITY 1995
CANCER IN TASMANIA INCIDENCE AND MORTALITY 1995 ACKNOWLEDGEMENTS The Department of Community and Health Services in Tasmania is acknowledged for financial support to the Registry. The work of collecting
More informationThe Future of Cancer. Lawrence Tsui Global Risk Products Actuary Swiss Reinsurance Company Hong Kong. Session Number: WBR8
Lawrence Tsui Global Risk Products Actuary Swiss Reinsurance Company Hong Kong Session Number: WBR8 Agenda Cancer the basics Cancer past and present Cancer the future CANCER THE BASICS Cancer the basics
More informationSession 4 Rebecca Poulos
The Cancer Genome Atlas (TCGA) & International Cancer Genome Consortium (ICGC) Session 4 Rebecca Poulos Prince of Wales Clinical School Introductory bioinformatics for human genomics workshop, UNSW 20
More informationSUPPLEMENTARY INFORMATION
Supplementary Information S3 TAM- family small molecule kinase inhibitors in development Compound Indication(s) Target Profile Develop Primary Target MERTK TYRO3 Other targets ment Phase Refs Cabozantinib
More information2010 Oncology Pharmacy Preparatory Review Course for Home Study Learning Objectives
2010 Oncology Pharmacy Preparatory Review Course for Home Study Learning Objectives Acute Leukemia/Tumor Lysis Syndrome John M. Valgus, Pharm.D., BCOP Hematology/Oncology Specialist University of North
More informationThe use of diagnostic FFPE material in cancer epidemiology research
The use of diagnostic FFPE material in cancer epidemiology research Neil O Callaghan Genetic Epidemiology Laboratory Department of Pathology The University of Melbourne www.pedigree.org.au Overview Who
More informationA Summary of Childhood Cancer Statistics in Australia,
What is the Australian Paediatric Cancer Registry (APCR)? The APCR is one of only a few national registries of childhood cancer in the world. It covers all Australian children aged 0-14 years old at diagnosis.
More informationAuditorium. Title: Welcome and Introduction by the Chairs Moderation: M. Pless, A. Cervantes ; Winterthur, CH, Valencia, ES
08-04-2017 12:45-13:00 Type: Educational session Title: Welcome and Introduction by the Chairs 1 2 1 2 Moderation: M. Pless, A. Cervantes ; Winterthur, CH, Valencia, ES 12:45-13:00 Welcome 13:00-13:15
More informationApplications. in Oncology
Kewal K. Jain Applications of Biotechnology in Oncology Applications of Biotechnology in Oncology Applications of Biotechnology in Oncology Kewal K. Jain, MD, FRACS, FFPM Jain PharmaBiotech, Basel, Switzerland
More informationNCCN National Comprehensive Cancer Network Directory Information
Please provide the information requested below. The information contained herein is for NCCN purposes only and will not be published without your express written consent below. Name: Last First Middle
More information